Cargando…

Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis

Multiple sclerosis (MS) is considered to be a central nervous system (CNS) chronic inflammatory demyelinating disease, affecting more than 2 million individuals worldwide. In this meta-analysis, we aimed to assess the safety and efficacy of autologous mesenchymal stem cells (aMSCs) in treating MS pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yang, Zhang, Xin, Xue, Hang, Liu, Lingling, Zhu, Jie, Jin, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942905/ https://www.ncbi.nlm.nih.gov/pubmed/31949442 http://dx.doi.org/10.1155/2019/8536785

Ejemplares similares

Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Nabizadeh, Fardin, et al.
Publicado: (2022)

Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis
por: Feng, Jenny, et al.
Publicado: (2019)

Autologous hematopoietic stem cell transplantation in progressive severe multiple sclerosis
por: Pandit, Awadh Kishor, et al.
Publicado: (2015)

Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant
por: Massey, Jennifer C., et al.
Publicado: (2018)

The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis
por: Willison, A. G., et al.
Publicado: (2022)

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
por: Casanova, Bonaventura, et al.
Publicado: (2017)

Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis
por: Lycke, Jan, et al.
Publicado: (2020)

Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis
por: Mohammadi, Reihane, et al.
Publicado: (2021)

Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis
por: Willison, A. G., et al.
Publicado: (2022)

B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
por: von Niederhäusern, Valentin, et al.
Publicado: (2022)

Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
por: FU, CHENGCHENG, et al.
Publicado: (2013)

Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis
por: Llufriu, Sara, et al.
Publicado: (2014)

Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis
por: Kasarełło, Kaja, et al.
Publicado: (2021)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021)

Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis
por: Burt, Richard K., et al.
Publicado: (2021)

Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
por: Ruder, Josefine, et al.
Publicado: (2022)

Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis
por: Zafeiri, Lida, et al.
Publicado: (2023)

Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline
por: Bayas, Antonios, et al.
Publicado: (2023)

Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis
por: Del Papa, Nicoletta, et al.
Publicado: (2018)

Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis
por: Simonsen, Cecilia Smith, et al.
Publicado: (2016)

Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing–Remitting Multiple Sclerosis Patients
por: Bertolotto, Antonio, et al.
Publicado: (2020)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
por: Ruder, Josefine, et al.
Publicado: (2021)

Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis
por: Uccelli, Antonio, et al.
Publicado: (2019)

Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
por: Moraes, Daniela A, et al.
Publicado: (2021)

Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use?
por: Rozier, Pauline, et al.
Publicado: (2018)

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation
por: Ma, Kewa, et al.
Publicado: (2021)

Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists
por: Das, Joyutpal, et al.
Publicado: (2019)

Transplantation of Autologous Mesenchymal Stem Cells for End-Stage Liver Cirrhosis: A Meta-Analysis Based on Seven Controlled Trials
por: Ma, Xiang-Rui, et al.
Publicado: (2015)

Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature
por: Patti, Francesco, et al.
Publicado: (2022)

Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis
por: Burman, Joachim, et al.
Publicado: (2023)

Mesenchymal properties of SJL mice-stem cells and their efficacy as autologous therapy in a relapsing–remitting multiple sclerosis model
por: Marin-Bañasco, Carmen, et al.
Publicado: (2014)

Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis
por: Chahine, Nassim Abi, et al.
Publicado: (2016)

Mesenchymal Stem Cells and Induced Pluripotent Stem Cells as Therapies for Multiple Sclerosis
por: Xiao, Juan, et al.
Publicado: (2015)

Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis
por: Petrou, Panayiota, et al.
Publicado: (2022)

Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Islam, Md Asiful, et al.
Publicado: (2023)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation
por: Hendrawan, Kevin, et al.
Publicado: (2022)

Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis
por: Das, J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i322l940s59fnkfprg3acr9f82